Brainstorm Cell Therapeutics Inc. (BCLI) Company Value to Net Income
The market trend for Brainstorm Cell (BCLI) visualized in monetary format on the GURU.Markets platform, where the indicator stands at -0.70, demonstrates the development of cellular treatment for nerve disorders. However, the global divide and sanctions are hindering cross-border testing and the supply of biomaterials. Meanwhile, Brainstorm Cell (BCLI) strictly adheres to ethical standards and is reducing laboratory waste, while its production facilities equipped with bioreactors continue to operate without disruption.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_BCLI_-_Brainstorm-Cell_-_PE-Multiple "BCLI: BrainStorm Cell Therapeutics Inc. P/E Multiple 07/04/2022 - 07/26/2025 | 👁️GURU.Markets👁️")
Analytical breakdowns for Brainstorm Cell
- stock quotes and analyst forecast:
- market capitalization details:
- balance sheet net asset value indicators:
- debt and solvency information:
Debt to Equity Ratio Brainstorm Cell|BCLI - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient BrainStorm Cell Therapeutics Inc.|BCLI - Company Total Debt|Debt to Book Capital Brainstorm Cell Therapeutics Inc.|BCLI - Company Long-Term Debt|Short-Term Debt BrainStorm Cell Therapeutics|Intermediate Coverage Ratio brainstorm-cell.com
- net income and valuation ratios data:
BCLI - Company Net Income|Future Profit Brainstorm Cell|BCLI - Price to Earnings Ratio|Future Price to Earnings Multiple Brainstorm Cell Therapeutics Inc.|BCLI - PEG Multiple|Enterprise Value to EBITDA Ratio Brainstorm Cell Therapeutics Inc.|BCLI - Operating profit EBITDA|Net earnings per one share for the last twelve months BrainStorm Cell Therapeutics|BCLI - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months brainstorm-cell.com|BCLI - Earnings per share growth in current year|Net earnings per share growth forecast for next year Brainstorm Cell
General company analysis:brainstorm-cell.com, BCLI
Investors are assessing the potential of Brainstorm Cell (BCLI) through the lens of the price-to-earnings ratio. This multiple determines the payback period for investments by comparing market capitalization with the business's actual earnings. Analyzing the company's base P/E allows for the identification of overpayment for the asset during periods of low liquidity. For a brand with the NurOwn platform, this indicator reflects the balance between therapeutic success and financial return. The precise dynamics of this metric confirm the fundamental stability of the issuer.
Analysis of competing companies
Price to Earnings Ratio BIIB|Price to Earnings Ratio Neurocrine Biosciences, Inc. (NBIX)|RGC (Regencell Bioscience Ltd) - Company Value to Net Income|P/E Multiple AXSM (Axsome Therapeutics Inc)|P/E Multiple ACADIA Corp ACAD|Xenon Pharmaceuticals - P/E Multiple|Business Payback Period vikingtherapeutics.com VKTX|Supernus (SUPN) - Price to Earnings Ratio|Price to Earnings Multiple CPRX|Price to Earnings Ratio Denali Therapeutics Inc|Harmony Corp (HRMY) - Business Payback Period|Price to Earnings Ratio BHVN (Biohaven Ltd.)|Market Price to Net Income Ratio AMLX|Price to Earnings Ratio Trevi Therapeutics, Inc. TRVI|Praxis Precision Medicines Inc (PRAX) - Market Cap to Earnings|AVXL - Price to Earnings Ratio|Company Value to Net Income CBLL (CeriBell EEG)|prothena.com (PRTA) - Price to Earnings Ratio|Price to Earnings Ratio Alector|Price to Earnings Ratio ANNX|OMER: Company Value to Net Income|P/E Multiple NGNE|Price to Earnings Ratio AC Immune Inc ACIU|P/E Multiple VYGR (Voyager Therapeutics)|neumoratx.com (NMRA) - Market Cap to Earnings|SCLX - Price to Earnings Ratio|TVGN: Price to Earnings Ratio|alphacognition.com (ACOG) - Price to Earnings Ratio|CGTX (Cognition Therapeutics Inc.) - Price to Earnings Ratio|IKT (Inhibikase Therapeutics) - P/E Multiple|Price to Earnings Ratio SAVA|P/E Multiple ASRT|Price to Earnings Ratio coyatherapeutics.com COYA|Price to Earnings Ratio Vistagen VTGN|Ovid Therapeutics Inc - Price to Earnings Ratio|Acumen Pharmaceuticals - P/E Multiple|Business Payback Period cervomed.com CRVO|alteritytherapeutics.com (ATHE) - Price to Earnings Ratio|Price to Earnings Multiple CLNN|PEPG (PepGen Inc) - P/E Multiple|Market Cap to Earnings Jupiter Neurosciences, Inc. JUNS|Price to Earnings Ratio RLMD (Relmada Therapeutics)|P/E Multiple annovisbio.com (ANVS)|Price to Earnings Ratio Grace Therapeutics GRCE|Company Value to Net Income AIFF|KLTO - Price to Earnings Ratio|Market Cap to Earnings NeuroSense Therapeutics|RVPH: P/E Multiple|MTVA (MetaVia) - Price to Earnings Ratio|Price to Earnings Ratio NeurAxis|HSDT: Company Value to Net Income|P/E Multiple PASG|P/E Multiple bionomics.com.au (NEUP)|P/E Multiple NERV (Minerva Neurosciences)|Business Payback Period athira.com (ATHA)|ADXN - Price to Earnings Ratio|ALZN (Alzamend Neuro, Inc.) - Price to Earnings Multiple|cyclerion.com (CYCN) - Price to Earnings Ratio|PTIX - Business Payback Period|Price to Earnings Ratio KTTA|CRGT (Cortigent Medical) - Market Price to Net Income Ratio|Price to Earnings Ratio Avenue Therapeutics, Inc. (ATXI)|CARA - Market Cap to Earnings|Price to Earnings Ratio Chromocell Therapeutics Corporation CHRO|Company Value to Net Income ELYM|ITCI - Price to Earnings Ratio|longboardpharma.com (LBPH) - Price to Earnings Ratio|MRNS (Marinus Pharmaceuticals, Inc.) - Price to Earnings Ratio|NKGen Biotech Inc - Company Value to Net Income|NRBO (NeuroBo) - P/E Multiple|Price to Earnings Ratio Sage Therapeutics Inc (SAGE)|P/E Multiple SNPX|TRVN - Market Cap to Earnings|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|anewmeds.com - Price to Earnings Ratio|CERE - Price to Earnings Ratio
